Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Overall, with its combination of leading and emerging businesses, Alphabet looks like one of the best AI stocks to own over ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

HONOR 400 5G is currently the smartphone to beat! Leading smart devices provider HONOR Philippines recently launched its newest flagship mid-range ...